[1] FRANCESCHI F,GASBARRINI A,POLYZOS S A,et al.Extragastric diseases and Helicobacter pylori[J].Helicobacter,2015,20(Suppl 1):40-46.
[2] FORD A C,FORMAN D,HUNT R H,et al.Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals:systematic review and meta-analysis of randomised controlled trials[J].BMJ,2014,348(4):g3174.
[3] MIENDJE-DEYI V Y,BONTEMS P,VANDERPAS J,et al.Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years(1990 to 2009) in Belgium[J].J Clin Microbiol,2011,49(6):2200-2209.
[4] WANG B,LV Z F,WANG Y H,et al.Standard triple therapy for Helicobacter pylori infection in China:a meta-analysis[J].World J Gastroenterol,2014,20(40):14973-14985.
[5] HAN R,LAN C,WU X,et al.Multicenter study of antibiotic resistance profile of H.pylori and distribution of CYPC19 gene polymorphisms in rural population of Chongqing,China[J].Gastroenterol Res Pract,2016,2016(4):1-6.
[6] XIE Y,ZHU Y,ZHOU H,et al.Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection[J].World J Gastroenterol,2014,20(32):11415-11421.
[7] MOAYYEDI P,HUNT R H.Helicobacter pylori public health implications[J].Helicobacter,2004,9(Suppl 1):67-72.
[8] 张万岱,胡伏莲,萧树东,等.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2010,15(5):265-270.
[9] MALFERTHEINER P,MEGRAUD F,O'MORAIN C,et al.Current European concepts in the management of Helicobacter pylori infection——the Maastricht Consensus Report.The European Helicobacter Pylori Study Group(EHPSG)[J].Eur J Gastroenterol Hepatol,1997,9(1):1-2.
[10] ZHOU L,ZHANG J,CHEN M,et al.A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection:a randomized multicenter trial[J].Am J Gastroenterol,2014,109(4):535-541.
[11] MALFERTHEINER P,BAZZOLI F,DELCHIER J C,et al.Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium,metronidazole,and tetracycline given with omeprazole versus clarithromycin-based triple therapy:a randomised,open-label,non-inferiority,phase 3 trial[J].Lancet,2011,377(9769):905-913.
[12] 刘文忠,谢勇.第四次全国幽门螺杆菌感染处理共识报告[J].中华内科杂志,2012,17(10):832-837.
[13] MALFERTHEINER P,MEGRAUD F,O'MORAIN C A,et al.Management of Helicobacter pylori infection-the Maastricht Ⅳ/Florence Consensus Report[J].Gut,2012,61(5):646-664.
[14] 成虹,胡伏莲,谢勇,等.中国幽门螺杆菌耐药状况以及耐药对治疗的影响-全国多中心临床研究[J].胃肠病学,2007,12(9):525-530.
[15] GOH K L,NAVARATNAM P.High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin,levofloxacin,and other antibiotics in Malaysia[J].Helicobacter,2011,16(3):241-245.
[16] SUN Q J,LIANG X,ZHENG Q,et al.Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai[J].World J Gastroenterol,2010,16(40):5118-5121.
[17] FURUTA T,SUGIMOTO M,SHIRAI N,et al.CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor[J].Pharmacogenomics,2007,8(9):1199-1210.
[18] DE MORAIS S M,WILKINSON G R,BLAISDELL J,et al.Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese[J].Mol Pharmacol,1994,46(4):594-598.
[19] SERRANO D,TORRADO S,TORRADO-SANTIAGO S,et al.The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments[J].Curr Drug Metab,2012,13(9):1303-1312. |